BioPlus Acquisition Corp. (BIOS) Terminates Avertix Deal, Will Liquidate
by Nicholas Alan Clayton on 2023-10-04 at 8:18am

BioPlus (NASDAQ:BIOS) announced this morning that it has mutually terminated its combination with medical device company Avertix.

Unlike with many terminations seen recently, this parting of ways does not appear to have come directly as a result of discouraging redemption results ahead of a major vote and the two sides are still well away from their December 31 outside date.

But, Avertix said in the press release that the two sides “agreed that the current market conditions are not conducive to completing the transaction on terms acceptable to both BIOS and Avertix stakeholders”.

At issue could have been the difficult terms for securing additional outside capital. BioPlus planned to pull together a $50 million PIPE at announcement and was beholden to a $40 million minimum cash condition. The two sides had not made any financing announcements since and in the current risk-off environment, many of the options available require concessions from either sponsor or target.

BioPlus CEO Ross Haghighat has insight into both sides interest as he also already has been serving as Avertix’s executive chairman and will continue on there despite the termination. It is the end of the road for BioPlus, however.

The SPAC noted that it will not seek an alternative business combination and will liquidate as soon as practicable beginning October 4 with a redemption rate of $10.79 after dissolution expenses.

Though unfortunate, the moves come alongside a bright spot of news among biotech de-SPACs as POINT Biopharma (NASDAQ:PNT) just announced it has agreed to be acquired at $12.50 per share by peer Eli Lilly (NYSE:LLY).

Recent Posts
by Kristi Marvin on 2023-11-25 at 11:45am

Terms Tracker for the Week Ending November 24, 2023 Welcome to our weekly column where we discuss the findings from our IPO terms tracker based on the previous week’s pricings. This being the Thanksgiving holiday week, we are thankful for a lot of things, but mostly that 2023 is almost over. It’s been a rough...

by Nicholas Alan Clayton on 2023-11-24 at 7:35am

At the SPAC of Dawn Though perhaps stuffed to the brim, SPAC activity continues this Thanksgiving Friday with votes by Clean Earth and Zalatoris to extend a deadline and amend trust contributions, respectively. At least seven de-SPACs are also reporting earnings today and will do so going into a futures market that is mostly green...

by Marlena Haddad on 2023-11-22 at 9:45am

IB Acquisition Corp. submitted its S-1 filing Friday afternoon for a $100 million IPO, coming right on the heels of Bayview Acquisition Corp, which also filed its S-1 that day. IB is also similar to Bayview in that its units do not feature a warrant but include 1 right for 1/10. However, its trust is slightly...

by Nicholas Alan Clayton on 2023-11-22 at 8:53am

Integrated Wellness (NYSE:WEL) announced in an 8-K filing that it agreed to transfer control of its sponsor to Sriram Associates, which will now take on the SPAC’s financial obligations and may appoint a new team. Sriram is acquiring 2,012,500 promote shares (70%) and 4,795,000 private placement warrants (70%) for the nominal purchase price of $1....

by Nicholas Alan Clayton on 2023-11-22 at 7:45am

At the SPAC of Dawn So far, seven SPACs have announced their liquidations this week and although some others may choose to use the holiday to quietly disband, this tends to be a positive week for equities in general. Going back to 1961, the S&P 500 has ended the Thanksgiving week with gains three-quarters of...


Copyright © 2023 SPACInsider, Inc. All Rights Reserved